| scholarly article | Q13442814 |
| P50 | author | Steven T. DeKosky | Q7615308 |
| Lewis Kuller | Q88077314 | ||
| P2093 | author name string | O L Lopez | |
| H M Gach | |||
| J T Becker | |||
| R Tracy | |||
| R A Sweet | |||
| Y F Chang | |||
| P D Mehta | |||
| P2860 | cites work | Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease | Q27860795 |
| Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease | Q28257707 | ||
| Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein | Q29547803 | ||
| Evaluation of dementia in the cardiovascular health cognition study | Q30766477 | ||
| The Modified Mini-Mental State (3MS) examination | Q34185551 | ||
| Neuropsychological characteristics of mild cognitive impairment subgroups | Q36142452 | ||
| Ischemic stress induces deposition of amyloid beta immunoreactivity in human brain | Q36790976 | ||
| The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia | Q39605807 | ||
| White matter hyperintensity on cranial magnetic resonance imaging: a predictor of stroke | Q40506135 | ||
| Serum creatinine levels correlate with plasma amyloid Beta protein | Q44129863 | ||
| Plasma amyloid beta, apolipoprotein E, lacunar infarcts, and white matter lesions | Q44817605 | ||
| Serum cystatin C advantageous compared with serum creatinine in the detection of mild but not severe diabetic nephropathy. | Q45156894 | ||
| High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. | Q45192211 | ||
| The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): socio-demographic correlates, reliability, validity and some norms. | Q45194604 | ||
| Plasma amyloid beta protein 42 in non-demented persons aged 75 years: effects of concomitant medication and medial temporal lobe atrophy | Q46510354 | ||
| Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy. | Q46886262 | ||
| Risk factors for 5-year mortality in older adults: the Cardiovascular Health Study | Q46892238 | ||
| Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan. | Q47831557 | ||
| Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). | Q48092766 | ||
| Risk factors for dementia in the cardiovascular health cognition study | Q48395439 | ||
| Relationship between ApoE, MRI findings, and cognitive function in the Cardiovascular Health Study | Q48530028 | ||
| Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels | Q48555754 | ||
| The molecular and genetic basis of AD: the end of the beginning: the 2000 Wartenberg lecture | Q48579960 | ||
| Circulating beta amyloid protein is elevated in patients with acute ischemic stroke | Q49093865 | ||
| Research evaluation and diagnosis of possible Alzheimer's disease over the last two decades: II. | Q49125001 | ||
| Differential modulation of plasma beta-amyloid by insulin in patients with Alzheimer disease. | Q50729448 | ||
| Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. | Q51762261 | ||
| Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. | Q51914558 | ||
| Longitudinal changes of CSF biomarkers in memory clinic patients. | Q51972050 | ||
| Incidence of dementia in mild cognitive impairment in the cardiovascular health study cognition study. | Q51977085 | ||
| Prevalence and severity of cognitive impairment with and without dementia in an elderly population. | Q52000587 | ||
| Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 1. | Q52004978 | ||
| Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. | Q52171785 | ||
| Altered amyloid protein processing in platelets of patients with Alzheimer disease. | Q53216222 | ||
| Characterization of apolipoprotein J-Alzheimer's A beta interaction | Q72132225 | ||
| A validation study of the Dementia Questionnaire | Q72174035 | ||
| Laboratory methods and quality assurance in the Cardiovascular Health Study | Q72588345 | ||
| Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice | Q73632001 | ||
| Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease | Q78245569 | ||
| Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk | Q79279445 | ||
| P433 | issue | 19 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | circulatory system | Q11068 |
| P304 | page(s) | 1664-1671 | |
| P577 | publication date | 2008-04-09 | |
| P1433 | published in | Neurology | Q1161692 |
| P1476 | title | Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study | |
| P478 | volume | 70 |
| Q40101067 | A Systematic Review of Longitudinal Studies Which Measure Alzheimer's Disease Biomarkers |
| Q34341870 | A blood-based predictor for neocortical Aβ burden in Alzheimer's disease: results from the AIBL study |
| Q35565629 | A genome-wide association meta-analysis of plasma Aβ peptides concentrations in the elderly |
| Q50576467 | A prospective study on blood Aβ levels and the cognitive function of patients with hemodialysis: a potential therapeutic strategy for Alzheimer's disease. |
| Q34716790 | Age-associated evolution of plasmatic amyloid in mouse lemur primates: relationship with intracellular amyloid deposition |
| Q37145570 | Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease |
| Q38543843 | Amyloid-β as a biomarker for Alzheimer's disease: quantification methods in body fluids |
| Q35166482 | Amyloid-β efflux from the central nervous system into the plasma |
| Q48450061 | Association of Plasma β-Amyloid with Cognitive Performance and Decline in Chronic Kidney Disease. |
| Q35024621 | Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline |
| Q48325860 | Associations between gonadotropins, testosterone and β amyloid in men at risk of Alzheimer's disease. |
| Q24622136 | Biological markers of amyloid beta-related mechanisms in Alzheimer's disease |
| Q30370745 | Biomarkers for cognitive impairment and dementia in elderly people. |
| Q24650667 | Biomarkers of Alzheimer's disease |
| Q37769463 | Biomarkers of Alzheimer's disease in body fluids |
| Q35060510 | Blood amyloid beta levels in healthy, mild cognitive impairment and Alzheimer's disease individuals: replication of diastolic blood pressure correlations and analysis of critical covariates |
| Q57295586 | Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic |
| Q35601036 | Blood-based biomarkers for Alzheimer's disease: plasma Aβ40 and Aβ42, and genetic variants |
| Q47378944 | Blood-based protein biomarkers for diagnosis of Alzheimer disease |
| Q64963501 | Canine Cognitive Dysfunction and Alzheimer’s Disease – Two Facets of the Same Disease? |
| Q37715542 | Chemically treated plasma Aβ is a potential blood-based biomarker for screening cerebral amyloid deposition |
| Q33752058 | Circulating biomarkers that predict incident dementia |
| Q59799715 | Correlations between plasma and PET beta-amyloid levels in individuals with subjective cognitive decline: the Fundació ACE Healthy Brain Initiative (FACEHBI) |
| Q45072634 | Diabetic Microvascular Disease: An Endocrine Society Scientific Statement |
| Q34077448 | Direct antigen detection from immunoprecipitated beads using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry; a new method for immunobeads-mass spectrometry (iMS). |
| Q98771760 | Dynamic Blood Concentrations of Aβ1-40 and Aβ1-42 in Alzheimer's Disease |
| Q35927794 | Empirically Derived Trajectories to Dementia Over 15 Years of Follow-up Identified by Using Mixed Membership Models |
| Q35920548 | Epidemiology of Alzheimer disease |
| Q94672454 | Evaluation of Brain Tortuosity Measurement for the Automatic Multimodal Classification of Subjects with Alzheimer's Disease |
| Q35821382 | Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI |
| Q26784569 | Fluid Biomarkers in Clinical Trials of Alzheimer's Disease Therapeutics |
| Q36953503 | Fluid biomarkers in Alzheimer's disease - current concepts |
| Q34597077 | Framingham Coronary Heart Disease Risk Score Can be Predicted from Structural Brain Images in Elderly Subjects |
| Q36712361 | Genome-wide haplotype association study identifies the FRMD4A gene as a risk locus for Alzheimer's disease |
| Q37464837 | Heart and brain tissue banks for research on co-occurring cardiovascular and neurological/psychiatric disorders |
| Q35085348 | Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: A case-control study |
| Q37987083 | Longitudinal plasma amyloid beta as a biomarker of Alzheimer's disease |
| Q27310276 | Longitudinal plasma amyloid beta in Alzheimer's disease clinical trials |
| Q37895050 | Meta-analysis of plasma amyloid-β levels in Alzheimer's disease. |
| Q35870513 | Midlife blood pressure, plasma β-amyloid, and the risk for Alzheimer disease: the Honolulu Asia Aging Study |
| Q27027319 | Mild cognitive impairment. Part 2: Biological markers for diagnosis and prediction of dementia in Alzheimer's disease |
| Q28740917 | Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis |
| Q37993988 | Nanopore analysis: An emerging technique for studying the folding and misfolding of proteins |
| Q48296591 | Novel therapeutic approach for Alzheimer's disease by removing amyloid beta protein from the brain with an extracorporeal removal system |
| Q48873840 | Patients that have Undergone Hemodialysis Exhibit Lower Amyloid Deposition in the Brain: Evidence Supporting a Therapeutic Strategy for Alzheimer's Disease by Removal of Blood Amyloid |
| Q37632619 | Patterns of compensation and vulnerability in normal subjects at risk of Alzheimer's disease |
| Q46397777 | Physical activity and amyloid-β plasma and brain levels: results from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing. |
| Q38793329 | Physical activity predicts reduced plasma β amyloid in the Cardiovascular Health Study |
| Q34292024 | Plasma Abeta42 and Abeta40 as markers of cognitive change in follow-up: a prospective, longitudinal, population-based cohort study |
| Q50354591 | Plasma Amyloid Is Associated with White Matter and Subcortical Alterations and Is Modulated by Age and Seasonal Rhythms in Mouse Lemur Primates. |
| Q91578256 | Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study |
| Q92436802 | Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition |
| Q36998414 | Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker |
| Q41690745 | Plasma amyloid β 42/40 ratios as biomarkers for amyloid β cerebral deposition in cognitively normal individuals |
| Q35185694 | Plasma amyloid-β and risk of Alzheimer's disease in the Framingham Heart Study |
| Q37169576 | Plasma amyloid-β as a predictor of dementia and cognitive decline: a systematic review and meta-analysis |
| Q55516241 | Plasma amyloid-β levels, cerebral atrophy and risk of dementia: a population-based study. |
| Q24193707 | Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI) |
| Q48702297 | Plasma β-amyloid levels in cerebral amyloid angiopathy-associated hemorrhagic stroke. |
| Q37297626 | Potential fluid biomarkers for pathological brain changes in Alzheimer's disease: Implication for the screening of cognitive frailty |
| Q44058569 | Potential therapeutic system for Alzheimer's disease: removal of blood Aβs by hemodialzyers and its effect on the cognitive functions of renal-failure patients |
| Q21245229 | Pro-inflammatory interleukin-18 increases Alzheimer's disease-associated amyloid-β production in human neuron-like cells |
| Q38125769 | Progress towards a consensus on biomarkers for Alzheimer's disease: a review of peripheral analytes. |
| Q92446371 | Reduced Levels of Cerebrospinal Fluid/Plasma Aβ40 as an Early Biomarker for Cerebral Amyloid Angiopathy in RTg-DI Rats |
| Q51812737 | Reduction of Alzheimer's disease amyloid-β in plasma by hemodialysis and its relation to cognitive functions. |
| Q35118684 | Relation between insulin, insulin-related factors, and plasma amyloid beta peptide levels at midlife in a population-based study |
| Q93055983 | Relationship of amyloid-β1-42 in blood and brain amyloid: Ginkgo Evaluation of Memory Study |
| Q36200059 | Reliable Measurements of the β-Amyloid Pool in Blood Could Help in the Early Diagnosis of AD. |
| Q37314262 | Serum Abeta levels as predictors of conversion to mild cognitive impairment/Alzheimer disease in an ADAPT subcohort |
| Q37387524 | Ten-year change in plasma amyloid beta levels and late-life cognitive decline |
| Q90371274 | Total Aβ42/Aβ40 ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis |
| Q49125728 | Toward the treatment for Alzheimer's disease: adsorption is primary mechanism of removing amyloid β protein with hollow-fiber dialyzers of the suitable materials, polysulfone and polymethyl methacrylate |
| Q53357937 | [Clinically validated molecular biomarkers of neurodegenerative dementia]. |
Search more.